Xencor (XNCR) Amortizatization of Intangibles (2015 - 2026)
Xencor (XNCR) posted quarterly Amortizatization of Intangibles of $128000.0 for Q1 2026, down 93.98% year-over-year from $2.1 million in Q1 2025, and down 62.35% quarter-over-quarter from $340000.0 in Q4 2025.
Powered by 
Analysis
Xencor (XNCR) Amortizatization of Intangibles (2015 - 2026) Analysis & Trends
Xencor (XNCR) has reported Amortizatization of Intangibles for 12 consecutive years, with $128000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 93.98% year-over-year to $128000.0; the TTM figure through Mar 2026 stood at $1.5 million (down 86.83% YoY), while the FY2025 annual figure was $3.5 million, down 78.3% from the prior year.
- Amortizatization of Intangibles eased to $128000.0 in Q1 2026 per XNCR's latest filing, from $340000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $6.9 million in Q1 2024 and bottomed at -$637000.0 in Q2 2025.
- Historically, Amortizatization of Intangibles has averaged $2.0 million across 5 years, with a median of $1.7 million in 2025.
- Annual changes were most pronounced in 2023 — Amortizatization of Intangibles surged 6452.54% — and 2025, when it plunged 113.19%.
- Xencor's Amortizatization of Intangibles stood at $782000.0 in 2022, then soared by 593.61% to $5.4 million in 2023, then tumbled by 110.9% to -$591000.0 in 2024, then surged by 157.53% to $340000.0 in 2025, then plunged by 62.35% to $128000.0 in 2026.
- Business Quant data shows XNCR's Amortizatization of Intangibles at $128000.0 in Q1 2026, $340000.0 in Q4 2025, and $1.7 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | 4.33 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 678,000.00 |
| 10 | Xencor | 2.02 Bn | 1.65 Bn | - | 7,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 7,000.00 |
| Mar 31, 2026 | 128,000.00 |
| Dec 31, 2025 | 340,000.00 |
| Sep 30, 2025 | 1.65 Mn |
| Jun 30, 2025 | -637,000.00 |
| Mar 31, 2025 | 2.13 Mn |
| Dec 31, 2024 | -591,000.00 |
| Sep 30, 2024 | 4.89 Mn |
| Jun 30, 2024 | 4.83 Mn |
| Mar 31, 2024 | 6.91 Mn |
| Dec 31, 2023 | 5.42 Mn |
| Sep 30, 2023 | 3.87 Mn |
| Jun 30, 2023 | 2.68 Mn |
| Mar 31, 2023 | 1.66 Mn |
| Dec 31, 2022 | 782,000.00 |
| Sep 30, 2022 | 59,000.00 |
| Jun 30, 2022 | -425,000.00 |
| Mar 31, 2022 | -543,000.00 |
| Dec 31, 2021 | -528,000.00 |
| Sep 30, 2021 | -921,000.00 |